NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation.
暂无分享,去创建一个
[1] E. Gelmann,et al. Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1. , 2008, Cancer research.
[2] Derek Y. Chiang,et al. Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.
[3] C. Bieberich,et al. Decreased NKX3.1 Protein Expression in Focal Prostatic Atrophy, Prostatic Intraepithelial Neoplasia, and Adenocarcinoma: Association with Gleason Score and Chromosome 8p Deletion , 2006 .
[4] T. Ludwig,et al. Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5. , 2006, Molecular endocrinology.
[5] N. Weigel,et al. Role of insulin‐like growth factor binding proteins in 1α,25‐dihydroxyvitamin D3‐induced growth inhibition of human prostate cancer cells , 2005, The Prostate.
[6] W. Willett,et al. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era , 2005, Cancer Causes & Control.
[7] E. Gelmann,et al. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. , 2005, Cancer research.
[8] B. G. Blijenberg,et al. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. , 2004, The Journal of clinical endocrinology and metabolism.
[9] P. Stattin,et al. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] S. Hankinson,et al. Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.
[11] T. Peters,et al. Screen‐detected prostate cancer and the insulin‐like growth factor axis: Results of a population‐based case‐control study , 2004, International journal of cancer.
[12] J. Witte,et al. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States) , 2003, Cancer Causes & Control.
[13] D. Albanes,et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. , 2003, Cancer research.
[14] J. Miano,et al. Serum response factor: toggling between disparate programs of gene expression. , 2003, Journal of molecular and cellular cardiology.
[15] Jeffrey A. Magee,et al. Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation. , 2003, Cancer cell.
[16] M. Stampfer,et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.
[17] R. Baxter,et al. Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.
[18] T. Barrette,et al. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. , 2002, Cancer research.
[19] M. Rechler,et al. Insulin-like Growth Factor (IGF)-binding Protein-3 Mutants That Do Not Bind IGF-I or IGF-II Stimulate Apoptosis in Human Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.
[20] Peter A. Humphrey,et al. Conditional Loss of Nkx3.1 in Adult Mice Induces Prostatic Intraepithelial Neoplasia , 2002, Molecular and Cellular Biology.
[21] R. Cardiff,et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[22] D. Bostwick,et al. Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer † , 2002, Genes, chromosomes & cancer.
[23] H. Koistinen,et al. Prostate‐specific antigen and other prostate‐derived proteases cleave IGFBP‐3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP‐3 , 2002, The Prostate.
[24] G E Walker,et al. Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves an Sp1/Sp3 multiprotein complex. , 2001, Endocrinology.
[25] T. Fears,et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[26] D. Ornstein,et al. Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. , 2001, The Journal of urology.
[27] R. Schwartz,et al. The Smooth Muscle γ-Actin Gene Promoter Is a Molecular Target for the Mouse bagpipe Homologue, mNkx3-1, and Serum Response Factor* , 2000, The Journal of Biological Chemistry.
[28] E. Riboli,et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. , 2000, Journal of the National Cancer Institute.
[29] O. Kallioniemi,et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. , 2000, Cancer research.
[30] E. Metter,et al. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. , 2000, The Journal of clinical endocrinology and metabolism.
[31] T. Wood,et al. Selective alterations in organ sizes in mice with a targeted disruption of the insulin-like growth factor binding protein-2 gene. , 2000, Molecular endocrinology.
[32] K. Devriendt,et al. Deletion of NKX2.1 gene encoding thyroid transcription factor-1 in two siblings with hypothyroidism and respiratory failure. , 2000, The Journal of pediatrics.
[33] E. Gelmann,et al. DNA-binding sequence of the human prostate-specific homeodomain protein NKX3.1. , 2000, Nucleic acids research.
[34] I. McCutcheon,et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. , 2000, Endocrine reviews.
[35] J. Seidman,et al. Loss of function and inhibitory effects of human CSX/NKX2.5 homeoprotein mutations associated with congenital heart disease. , 2000, The Journal of clinical investigation.
[36] J. Seidman,et al. Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. , 1999, The Journal of clinical investigation.
[37] R. Cardiff,et al. Roles for Nkx3.1 in prostate development and cancer. , 1999, Genes & development.
[38] C. Sawyers,et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[39] C. Mantzoros,et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. , 1998, Journal of the National Cancer Institute.
[40] S. Mohan,et al. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. , 1997, Endocrine reviews.
[41] M. Augustus,et al. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. , 1997, Cancer research.
[42] S. Mohan,et al. Insulin‐Like Growth Factor (IGF) System Components in Human Prostatic Cancer Cell‐Lines: LNCaP, DU145, and PC‐3 Cells , 1996, International journal of urology : official journal of the Japanese Urological Association.
[43] D. Leroith,et al. The Role of the Tyrosine Kinase Domain of the Insulin-like Growth Factor-I Receptor in Intracellular Signaling, Cellular Proliferation, and Tumorigenesis (*) , 1995, The Journal of Biological Chemistry.
[44] D. Clemmons,et al. Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.
[45] A. Sommer,et al. Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3. , 1994, Growth regulation.
[46] D. Peehl,et al. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. , 1994, The Journal of endocrinology.
[47] L. Giudice,et al. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. , 1992, The Journal of clinical endocrinology and metabolism.
[48] J. Wallace,et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. , 1992, Journal of molecular endocrinology.
[49] J. Wallace,et al. Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expression in Escherichia coli as fusion proteins. , 1992, Journal of molecular endocrinology.
[50] Jianfeng Xu,et al. Germ-line mutation of NKX3.1 cosegregates with hereditary prostate cancer and alters the homeodomain structure and function. , 2006, Cancer research.
[51] Noel S Weiss,et al. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin‐like growth factor I, insulin‐like growth factor binding protein 3, and insulin , 2005, Cancer.
[52] M. Stampfer,et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.
[53] E. Ludolphy. [Cancer cells]. , 1950, Medizinische Monatsschrift.